SDGRSchrodinger Inc

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

What Does Schrodinger Inc (SDGR)'s 2026 Outlook Reveal...

Schrdinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the companys common stock to seven newly hired employees. These grants were made pursuant to the companys 2021 Inducement Equity Incentive Plan...

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It PR Newswire NEW YORK, June 16, 2026 Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful...

Schrdinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the companys common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the companys common...

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti...

Schrodinger (SDGR) delivered earnings and revenue surprises of -44.64% and -2.17%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger (NASDAQ:SDGR - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of...

Schrdinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended March 31, 2026. Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth...